Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults

被引:1
|
作者
Shin, Thomas [1 ]
Wells, Chad R. [2 ]
Shoukat, Affan [3 ]
Potter-Schwartz, Lilia [2 ]
Langevin, Edith [4 ]
Langley, Joanne M. [5 ]
Galvani, Alison P. [2 ]
Moghadas, Seyed M. [6 ]
机构
[1] Sanofi, Hlth Econ & Outcomes Res, Bridgewater, NJ USA
[2] Yale Sch Publ Hlth, Ctr Infect Dis Modeling & Anal, New Haven, CT USA
[3] Univ Regina, Dept Math & Stat, Regina, SK, Canada
[4] Sanofi, Hlth Econ Value Assessment, Lyon, France
[5] Dalhousie Univ, Canadian Ctr Vaccinol, Halifax, NS, Canada
[6] York Univ, Agent Based Modelling Lab, 4700 Keele St, Toronto, ON M3J 1P3, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
AGED; 13-17; YEARS; UNITED-STATES; EPIDEMIOLOGY; PREVENTION; COVERAGE;
D O I
10.1001/jamanetworkopen.2024.43551
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance Beginning in 2005, the US implemented routine immunization of adolescents with a quadrivalent conjugate vaccine (MenACWY) for the prevention of invasive meningococcal disease (IMD). Objectives To assess whether MenACWY immunization was associated with a reduced IMD burden among the US adolescent population and how the downward trajectory of IMD that began in the mid-1990s might have evolved in the absence of vaccination efforts. Design, Setting, and Participants In this decision analytical study, a bayesian hierarchical Poisson regression model was developed to investigate the potential trajectory of IMD among US adolescents and young adults without vaccination and evaluate the direct association of vaccination with IMD burden. The model included the entire age-stratified US population and was fitted to national incidence data for serogroups C, W, and Y from January 1, 2001, to December 31, 2021, with stratification by vaccination status for IMD cases. Intervention Simulated counterfactual scenario of absent vaccination from 2005 to 2021, while retaining the incidence rate of IMD for unvaccinated individuals estimated during model fitting. Main Outcomes and Measures The main outcomes were the estimated numbers of IMD cases and deaths averted by MenACWY vaccination among US adolescents and young adults aged 11 to 23 years. Results Among the entire US population from 2005 to 2021, MenACWY vaccination prevented an estimated 172 (95% credible interval [CrI], 85-345) cases of IMD among US adolescents 11 to 15 years of age and 328 (95% CrI, 164-646) cases of IMD among those aged 16 to 23 years. Absent vaccination, the cumulative incidence of IMD in these age groups would have been at least 59% higher than reported over the same period with vaccination. Using case fatality rates of unvaccinated individuals derived from national data, vaccination averted an estimated 16 (95% CrI, 8-31) deaths among adolescents aged 11 to 15 years and 38 (95% CrI, 19-75) deaths among those aged 16 to 23 years. Conclusions and Relevance This decision analytical model suggests that the MenACWY vaccination program in the US was associated with a reduced burden of meningococcal disease. Without vaccination, the incidence rates per 100 000 adolescents and young adults would have been substantially higher than those observed during the vaccine era.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults
    Nolan, Terry
    O'Ryan, Miguel
    Wassil, James
    Abitbol, Veronique
    Dull, Peter
    VACCINE, 2015, 33 (36) : 4437 - 4445
  • [2] Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine
    Khalil, Mohamed
    Al-Mazrou, Yagob
    Findlow, Helen
    Chadha, Helen
    Castells, Valerie Bosch
    Oster, Philipp
    Borrow, Ray
    VACCINE, 2014, 32 (43) : 5715 - 5721
  • [3] Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age
    Baxter, Roger
    Baine, Yaela
    Ensor, Kathleen
    Bianco, Veronique
    Friedland, Leonard R.
    Miller, Jacqueline M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (03) : E41 - E48
  • [4] A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults
    Ostergaard, Lars
    Vesikari, Timo
    Absalon, Judith
    Beeslaar, Johannes
    Ward, Brian J.
    Senders, Shelly
    Eiden, Joseph J.
    Jansen, Kathrin U.
    Anderson, Annaliesa S.
    York, Laura J.
    Jones, Thomas R.
    Harris, Shannon L.
    O'Neill, Robert
    Radley, David
    Maansson, Roger
    Pregaldien, Jean-Louis
    Ginis, John
    Staerke, Nina B.
    Perez, John L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (24) : 2349 - 2362
  • [5] Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease
    Hedari, Carine P.
    Khinkarly, Rima W.
    Dbaibo, Ghassan S.
    INFECTION AND DRUG RESISTANCE, 2014, 7 : 85 - 99
  • [6] Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi
    Kensinger, Richard
    Arunachalam, Arun B.
    GLYCOCONJUGATE JOURNAL, 2022, 39 (03) : 381 - 392
  • [7] Immunogenicity and Safety of Concomitant Administration of a Combined Hepatitis A/ B Vaccine and a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults
    Alberer, Martin
    Burchard, Gerd
    Jelinek, Tomas
    Reisinger, Emil C.
    Meyer, Seetha
    Forleo-Neto, Eduardo
    Dagnew, Alemnew F.
    Arora, Ashwani Kumar
    JOURNAL OF TRAVEL MEDICINE, 2015, 22 (02) : 105 - 114
  • [8] Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination
    Burman, Cynthia
    Serra, Lidia
    Nuttens, Charles
    Presa, Jessica
    Balmer, Paul
    York, Laura
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (02) : 459 - 469
  • [9] Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure
    Wang, Xin
    Shutt, Kathleen A.
    Vuong, Jeni T.
    Cohn, Amanda
    MacNeil, Jessica
    Schmink, Susanna
    Plikaytis, Brian
    Messonnier, Nancy E.
    Harrison, Lee H.
    Clark, Thomas A.
    Mayer, Leonard W.
    JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (12) : 1887 - 1894
  • [10] Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra
    Reisinger, Keith S.
    Baxter, Roger
    Block, Stanley L.
    Shah, Jina
    Bedell, Lisa
    Dull, Peter M.
    CLINICAL AND VACCINE IMMUNOLOGY, 2009, 16 (12) : 1810 - 1815